Download PDF
Thromb Haemost 1992; 68(04): 400-403
DOI: 10.1055/s-0038-1646285
Original Article
Schattauer GmbH Stuttgart

Enhancement of Spontaneous Fibrinolytic Activity in Diabetic Retinopathy

Helmut Ostermann
1   The Department of Internal Medicine, University of Münster, FRG
,
Diethelm Tschöpe
3   The Department of Diabetes Research Institute, University of Düsseldorf, FRG
,
Wolfgang Greber
4   The Department of Ophthalmology, University of Düsseldorf, FRG
,
Hans-Werner Meyer-Rüsenberg
2   The Department of Ophthalmology, University of Münster, FRG
,
Jürgen van de Loo
1   The Department of Internal Medicine, University of Münster, FRG
› Author Affiliations
Further Information

Publication History

Received 23 December 1991

Accepted after revision 20 May 1992

Publication Date:
04 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The fibrinolytic system was studied in 96 patients with type I diabetes mellitus. Patients were grouped according to their degree of retinopathy; 38 patients with no evidence of retinopathy, 28 patients with background retinopathy and 30 patients with proliferative retinopathy. Thirty healthy individuals served as controls. The basal fibrinolytic activity as measured by clot lysis time and t-PA activity was increased in diabetic patients. This was associated with low levels of plasminogen activator inhibitor. Increased levels of D-dimer in diabetic patients further indicate enhanced in vivo fibrinolysis. The increase in fibrinolytic activity was highest in diabetics without retinopathy, and decreased with increasing retinopathy. Endothelial release of t-PA after venous occlusion was not different between controls and all diabetic groups. These findings suggest that in type I diabetics the fibrinolytic system is in an activated state. With worsening of retinopathy this increase in fibrinolytic activity diminishes.

 

  • REFERENCES

  • 1 Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989; 107: 244-249
    CrossrefPubMedGoogle Scholar
  • 2 Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360
    CrossrefPubMedGoogle Scholar
  • 3 Merimee TJ. Diabetic retinopathy. A synthesis of perspectives. N Engl J Med 1990; 322: 978-983
    CrossrefPubMedGoogle Scholar
  • 4 Engerman RL. Pathogenesis of diabetic retinopathy. Diabetes 1989; 38: 1203-1206
    PubMedGoogle Scholar
  • 5 Christe M, Fritschi J, Lämmle B, Trah TH, Marbet GA, Berger W, Duckert F. Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 1984; 52: 138-142
    PubMedGoogle Scholar
  • 6 Tschöpe D, Roesen P, Kaufmann L. et al Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 1990; 20: 595-599
    PubMedGoogle Scholar
  • 7 Mustard JF, Packham MA. Platelets and diabetes mellitus. N Engl J Med 1984; 311: 665-667
    CrossrefPubMedGoogle Scholar
  • 8 Lorenzi M, Cagliero E. Pathobiology of endothelial and other vascular cells in diabetes mellitus. Diabetes 1991; 40: 653-659
    CrossrefPubMedGoogle Scholar
  • 9 Ostermann H, van de Loo J. Factors of the hemostatic system in diabetic patients. A survey of controlled studies. Haemostasis 1986; 16: 385-416
    PubMedGoogle Scholar
  • 10 Takahashi H, Tsuda A, Tatewaki W, Wada K, Niwano H, Shibata A. Activation of blood coagulation and fibrinolysis in diabetes mellitus: Evaluation by plasma levels of thrombin-antithrombin III complex and plasmin-alpha2-plasmin inhibitor complex. Thromb Res. 1989; 55: 727-735
    PubMedGoogle Scholar
  • 11 Small M, Kluft C, MacCuish AC, Lowe GDO. Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care 1989; 12: 655-658
    CrossrefPubMedGoogle Scholar
  • 12 Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic Peptide Substrates: Chemical and Clinical Usage.. Scully MF, Kakkar VV. (eds) Churchill Livingstone, Edinburgh: 1979. pp 128-139
    Google Scholar
  • 13 Teger-Nilsson AC, Friberger P, Gyzander E. Determination of a new, rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403-409
    CrossrefPubMedGoogle Scholar
  • 14 Blix S. Studies on the fibrinolytic system in the euglobulin fraction of human plasma. Scand J Clin Lab Invest 1961; 13 (Suppl58): 03-19
    PubMedGoogle Scholar
  • 15 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 16 Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160-2165
    PubMedGoogle Scholar
  • 17 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
    PubMedGoogle Scholar
  • 18 Amiral J, Plassart V, Minard F. Measurement and clinical relevance of D-Dimer by ELISA. In: Fibrinogen and Its Derivatives.. Müller-Berghaus G, Scheefers-Borchel U, Selmyr E, Henschen A. (eds) Excerpta Medica, Amsterdam: 1986. pp 285-290
    Google Scholar
  • 19 Bern MM, Cassani MP, Horton J, Rand L, Davis G. Changes of fibrinolysis and factor VIII coagulant, antigen and ristocetin cofactor in diabetes mellitus and atherosclerosis. Thromb Res 1980; 19: 831-839
    CrossrefPubMedGoogle Scholar
  • 20 Sharma SC. Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in juvenile-onset and maturity-onset diabetes mellitus. J Clin Pathol 1981; 34: 501-503
    CrossrefPubMedGoogle Scholar
  • 21 Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WRS, Stirling Y. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; ii: 964-966
    PubMedGoogle Scholar
  • 22 Knaap JHvd, de Boer AC, Pannebakker MAG, van Heerde W, den Ottolander GJH. The effect of diabetes regulation on platelet release, fibrinolysis and coagulation tests, before and after stimulation with DDAVP. Thromb Haemostas 1985; 53: 118-121
    PubMedGoogle Scholar
  • 23 Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72
    CrossrefPubMedGoogle Scholar
  • 24 Alessi MC, Juhan-Vague I, Kooistra T, Declerk PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60: 491-494
    PubMedGoogle Scholar
  • 25 Juhan-Vague I, Vague P, Alessi MC. et al Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabetes Metab 1987; 13: 331-336
    PubMedGoogle Scholar
  • 26 Grant PJ, Kruithof EKO, Felley CP, Felber JP, Bachmann F. Shortterm infusion of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 1990; 79: 513-516
    CrossrefPubMedGoogle Scholar
  • 27 Van Loon BJP, Debart ACW, Radder JK, Frolich M, Kluft C, Meinders AE. Acute exogenous hyperinsulinemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans. Fibrinolysis 1990; 4: 93-94
    PubMedGoogle Scholar
  • 28 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
    PubMedGoogle Scholar
  • 29 Marongui F, Conti M, Mameli G, Sorano GG, Cossu E, Cirillo R, Balestrieri A. Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity? Thromb Res. 1990; 58: 91-99
    PubMedGoogle Scholar
  • 30 Tsianos EB, Stathakis NE. Soluble fibrin complexes and fibrinogen heterogeneity in diabetes mellitus. Thromb Haemostas 1980; 44: 130-134
    PubMedGoogle Scholar
  • 31 Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic retinopathy. Lancet 1989; i: 461-463
    PubMedGoogle Scholar
  • 32 Ramsay RC, Goetz FC, Sutherland DER, Mauer SM, Robison LL, Cantrill HL, Knobloch WH, Najarian JS. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 208-204
    CrossrefPubMedGoogle Scholar
  • 33 KROC Colloborative Study Group Diabetic retinopathy after two years of intensified insulin treatment. JAMA 1988; 260: 37-41
    CrossrefPubMedGoogle Scholar
  • 34 Mangel WF. Enzyme systems – better reception for urokinase. Nature 1990; 344: 488-489
    CrossrefPubMedGoogle Scholar
  • 35 Goldfarb RH, Murano G, Brundage R, Siegal GP, Terranova V, Garbisa S, Liotta LA. Degradation of glycoprotein and collageneous components of the basement membrane: studies with urokinase-type plasminogen activator, alpha-thrombin and plasmin. Semin Thromb Hemostas 1986; 12: 335-336
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Högemann B, Balleisen L, Rauterberg J, Voss B, Gerlach U. Basement membrane components (7S collagen, laminin P1) are increased in sera of diabetics and activate platelets in vitro. Haemostasis 1986; 16: 428-432
    PubMedGoogle Scholar
  • 37 Triolo DE, Giardina E, Zarcone MR, Seddio G, Bompiani GD. Serum levels of type III procollagen peptide in diabetes mellitus. Horm Metab Res 1989; 21: 77-80
    Article in Thieme ConnectPubMedGoogle Scholar